Explore News By Topic
08/28/2018
The Prostate Cancer Foundation Announces Recipients of the 2018 PCF Young Investigator Awards
LOS ANGELES, Calif., August 28, 2018 – The Prostate Cancer Foundation (PCF) announced today that it has granted a total of $6 million to 29 promising early career scientists dedicated to advancing critical research in developing better early detection methods, improving life-saving treatments and finding a cure for prostate cancer.... Read More
08/16/2018
The Prostate Cancer Foundation and the Movember Foundation Announce 2018 Challenge Awards Winners
SANTA MONICA, Calif., August 16, 2018 – The Prostate Cancer Foundation (PCF) and the Movember Foundation today announced four new Movember Foundation-PCF Challenge Award teams at some of the world’s leading academic research institutions will receive a total of $3.5 million to support cross-disciplinary pioneering research toward the goal of finding a cure... Read More
08/01/2018
The Prostate Cancer Foundation Appoints Christine Jones as Chief Operating Officer
SANTA MONICA, Calif., August 1, 2018 – The Prostate Cancer Foundation (PCF) today announced that Christine Jones has been appointed Chief Operating Officer effective immediately reporting to Jonathan W. Simons, MD, President and Chief Executive Officer (CEO). In this role, Ms. Jones will contribute to the strategic growth of the... Read More
07/19/2018
Genomic Landscape of Metastatic Prostate Cancer Unveiled in New Study
A comprehensive genetic analysis of metastatic prostate cancer has, for the first time, revealed a number of major ways in which abnormal alterations of the genome propel this aggressive form of the disease. As reported in the July 19, 2018 issue of Cell, a team led by investigators at UC... Read More
07/17/2018
NIH and Prostate Cancer Foundation launch large study on aggressive prostate cancer in African-American men
The largest coordinated research effort to study biological and non-biological factors associated with aggressive prostate cancer in African-American men has begun. The $26.5 million study is called RESPOND, or Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress. It will... Read More
07/13/2018
FDA Approves Enzalutamide (Xtandi) for Non-Metastatic Castration-Resistant Prostate Cancer
July 13, 2018 – Today the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC). Non-metastatic CRPC is a clinical state in which PSA levels begin to rise in patients being treated with androgen deprivation therapy (ADT), but metastases are... Read More
07/11/2018
Deadly Form of Advanced Prostate Cancer is Common, Calls for Distinct Treatment
Original article issued by UCSF News. A new study of prostate cancer in 202 men, whose cancers had spread and were resistant to standard treatment, found that a surprisingly large number of these cancers – about 17 percent – belong to a deadlier subtype of metastatic prostate cancer. Previously, it... Read More
07/10/2018
Tumors Grown in the Lab Provide Insights on Rare Prostate Cancer
Original article issued by Weill Cornell Medicine. Growing miniature tumors from patient’s cells in the laboratory may help scientists personalize treatments for those with a rare form of prostate cancer, according a study by Weill Cornell Medicine and NewYork-Presbyterian scientists. Patients with prostate cancer often receive therapies that reduce levels... Read More
06/26/2018
How Your Spit May Help Doctors Diagnose Prostate Cancer
Original article issued by Healthline. It might seem inconceivable that a simple saliva test can tell you your chances of developing cancer. But evidently it can. And the reason is crude but simple: Your genetic makeup can be found in your spit. Scientists are now able to extract DNA from cells... Read More
06/25/2018
Researchers find prostate cancer drug byproduct can fuel cancer cells
Original press release issued by: Cleveland Clinic. A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic. The findings may provide important information for identifying which patients potentially fare better when treated with... Read More